Answers are grounded in this paper and cite their sources.
Retrospective analysis demonstrates decreased network connectivity issues in co-morbid SUDs, suggesting naltrexone's potential therapeutic benefits.
Co-morbid substance use disorders ( SUDs ) are common but difficult to study due to the complex, interacting, and overlapping mechanisms through which they affect brain networks. Many datasets collected to investigate a specific SUD include participants with co-morbid SUDs. While most studies treat comorbid SUDs as covariates of no interest, these covariates also contain untapped information. This is particularly relevant as cannabis use disorder ( CanUD ) has become increasingly prevalent and co-morbid with other SUDs that have been more thoroughly studied. While treatments have been established for multiple SUDs, none have been approved for CanUD, although naltrexone ( NTX ) has been associated with reduced use. Here, we conducted a retrospective secondary analysis of functional magnetic resonance imaging ( fMRI ) data from individuals with primary opioid use disorder ( OUD ) with co-morbid CanUD, alcohol use disorder ( AUD ), or cocaine use disorder ( CocUD ), while controlling for opioid use. All participants underwent imaging prior to receiving a therapeutic dose of long-acting intramuscular NTX (Vivitrol ® ), an approved treatment for OUD and AUD but not for CocUD, and again two weeks post-administration. At baseline, OUD individuals with co-morbid CanUD, AUD, or CocUD exhibited distinct functional connectivity ( FC ) alterations compared to those with OUD-only. These differences were greater in younger participants and primarily involved the default mode network. Following NTX administration, FC differences between the co-morbid CanUD and OUD-only groups globally diminished. A similar FC response to NTX was observed in the parietal, subcortical, sensory, and cerebellar networks in the co-morbid AUD group. In contrast, little change in FC was observed in co-morbid CocUD. These findings, combined with prior evidence that NTX reduces cannabis use by dampening the experience of reward, suggest NTX may hold promise as a treatment for CanUD.
No takes yet. Share an insight, caveat, or question.
Brier et al. (2025) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: